Phase II Trial of AZD6738 Alone and in Combination With Olaparib
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ATR kinase inhibitor AZD6738 works alone or in
combination with olaparib in treating participants with renal cell carcinoma, urothelial
carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear
cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the
body. ATR kinase inhibitor AZD6738 and olaparib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase
inhibitor AZD6738 with or without olaparib may work better in treating participants with
solid tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Rahul Aggarwal University of California, San Francisco